Mr Mark Bishop

(he/him)

2021

• Hrastelj, J. et al. 2021. CSF-resident CD4+ T-cells display a distinct gene expression profile with relevance to immune surveillance and multiple sclerosis. Brain Communications (10.1093/braincomms/fcab155)

2005

• Sansom, O. J. et al. 2005. MBD2 deficiency does not accelerate p53 mediated lymphomagenesis. Oncogene 24 (14), pp.2430-2432. (10.1038/sj.onc.1208166)

2004

• Sansom, O. J. et al. 2004. MBD4 deficiency does not increase mutation or accelerate tumorigenesis in mice lacking MMR. Oncogene 23 (33), pp.5693-5696. (10.1038/sj.onc.1207767)

2003

• Sansom, O. J. et al. 2003. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nature Genetics 34 (2), pp.145-147. (10.1038/ng1155)
• Sansom, O. J. et al. 2003. Apoptosis and mutation in the murine small intestine: loss of MIh1- and Pms2-dependent apoptosis leads to increased mutation in vivo. DNA Repair 2 (9), pp.1029-1039. (10.1016/S1568-7864(03)00111-3)
• Sansom, O. J. et al. 2003. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 22 (46), pp.7130-7136. (10.1038/sj.onc.1206850)

2002

• Millar, C. B. et al., 2002. Enhanced CpG Mutability and Tumorigenesis in MBD4-Deficient Mice. Science , pp.403-405. (10.1126/science.1073354)